Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;1(4):e003723.
doi: 10.1161/JAHA.112.003723. Epub 2012 Aug 24.

Tachometer for reverse cholesterol transport?

Arnold Eckardstein  1
Affiliations

Tachometer for reverse cholesterol transport?

Arnold Eckardstein. J Am Heart Assoc. 2012 Aug.
No abstract available

Keywords: cholesterol efflux; high-density lipoprotein; reverse cholesterol transport.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Key steps of RCT. HDL metabolism is a multistep process that involves the secretion of lipid-free apolipoproteins by the liver or intestine; acquisition of phospholipids and cholesterol from cells via ATP-binding cassette transporters (ABC) A1 and G1, as well as via scavenger receptor BI (SR-BI); maturation by LCAT-mediated cholesterol esterification and phospholipid transfer protein (PLTP)–mediated particle fusion; and final delivery of lipids to the liver, either directly via SR-BI or indirectly via cholesteryl ester transfer protein (CETP)–mediated transfer to LDL. Moreover, at least one as yet unidentified receptor stimulated by activation of the ektoATPase/P2Y13-axis mediates holoparticle uptake of HDL. The liver secretes cholesterol into the bile, either directly via ATP cassette transporters G5 and G8 or indirectly after oxidation to bile acid secretion via ATP cassette transporter B11. In addition to this classic hepatobiliary RCT mediated by HDL, there is increasing evidence for direct and HDL-independent transintestinal cholesterol excretion (TICE).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000 - PMC - PubMed
    1. von Eckardstein A. Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. Expert Rev Cardiovasc Ther. 2010;8:345-358 - PubMed
    1. Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4:251-268 - PMC - PubMed
    1. Landmesser U, von Eckardstein A, Kastelein J, Deanfield J, Lüscher TF. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J. 2012;33:1712-1715 - PubMed
    1. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AF, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet Published online before print May 17, 2012 - PMC - PubMed

LinkOut - more resources